The company's principal activities are to research and develop novel therapeutics for the treatment of inflammatory disorders. The company uses its collaborative partners to conduct and fund on-going research and development on those components of its portfolio that had not been out licensed. The company undertakes clinical trials to develop protease inhibitors and bradykinin antagonists in treatment of acute respiratory distress and brain injury. The company in response to disappointing test results and its loss of collaborative partner support discontinued all research and development activities. The company also decommissioned its laboratories and sold all of its remaining scientific, technical and office equipment. The company's strategy is to seek collaborative partners to conduct and fund future research and development on the components of its portfolio.
